Positive results for MAIA’s SCLC treatment published in Nature Communications
The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide
Read More
Tag: small cell lung cancer
AZ’ Imfinzi bags new approval for lung cancer
The EC has cleared its use for the treatment of extensive-stage small cell lung cancer
Read More
Imfinzi shows survival benefit in aggressive lung cancer
The drug cut the risk of death by 27%.
Read More
Imfinzi found to improve survival in small cell lung cancer
Limited treatment options are available for patients with this most aggressive type of lung cancer.
Read More
Roche bags small cell lung cancer nod for Tecentriq
Roche’s Tecentriq has won US clearance for use in combination with carboplatin and etoposide (chemotherapy) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in the US, offering patients the first new treatment in more than 20 years.
Read More
Opdivo fails to hit key target in small cell lung cancer study
Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.
Read More
US nod for Opdivo in pre-treated small cell lung cancer
US regulators have further expanded the scope of Bristol Myers Squibb’s Opdivo, approving its use for a previously treated small cell lung cancer.
Read More
- KCL researchers identify key features of autoimmune diseases present in the gut
- Vicore and Endeavor’s therapies show promise in treating IPF
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
